EMEA-001268-PIP01-12-M05
Key facts
Invented name |
Repatha
|
Active substance |
Evolocumab
|
Therapeutic area |
Cardiovascular diseases
|
Decision number |
P/0104/2018
|
PIP number |
EMEA-001268-PIP01-12-M05
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Amgen Europe B.V
Tel. +44 (0)1223 420305
E-mail: medinfointernational@amgen.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-001268-PIP01-12-M05
|
Compliance opinion date |
24/06/2022
|
Compliance outcome |
positive
|